NCT06377852 2026-03-18
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
American Society of Clinical Oncology
Phase 3 Recruiting
Clinical Trials
20 trialsNCT07237256 2026-03-16
NoLEEta
UNICANCER
Phase 3 Recruiting
NCT05843253 2026-03-04
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
Phase 2 Recruiting
NCT05467891 2026-02-27
RaPhLRR
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT05996107 2026-01-28
Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer
University of Michigan Rogel Cancer Center
Phase 1 Recruiting
NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT06409390 2025-12-04
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT04116541 2025-11-21
MegaMOST
Centre Leon Berard
Phase 2 Recruiting
NCT06062498 2025-10-20
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
Northwestern University
Phase 2 Recruiting
NCT05900206 2025-09-02
ARIADNE
Karolinska University Hospital
Phase 2 Recruiting
NCT06953882 2025-07-14
SELECT
Yale University
Phase 2 Recruiting
NCT05319873 2025-05-13
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
Jonsson Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT04315233 2025-04-22
CHARGE
University of Utah
Phase 1 Recruiting
NCT05664893 2025-03-30
CALHYS
Centre Antoine Lacassagne
Phase 1/2 Recruiting
NCT05296746 2025-03-18
RIBOLARIS
SOLTI Breast Cancer Research Group
Phase 2 Recruiting
NCT05816655 2025-03-18
Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Korea University Guro Hospital
Phase 2 Recruiting
NCT06805812 2025-02-03
PALMARES-2
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Recruiting
NCT06587789 2024-11-21
Ribociclib in Combination With Adjuvant Endocrine Therapy for Patients With Early High-risk HR+HER2- Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Recruiting
NCT05452213 2023-04-18
CAPTOR-BC
Institut fuer Frauengesundheit
Phase 4 Recruiting
NCT05766410 2023-03-16
ORACLE-RIPA
National Taiwan University Hospital
Phase 2 Recruiting